Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 16, 2024
Chronic
graft-versus-host
disease
(GVHD)
is
a
major
complication
after
allogeneic
hematopoietic
stem
cell
transplantation
(HSCT).
GVHD
may
have
atypical
manifestations
affecting
non-classical
organs.
The
diagnosis
in
patients
with
of
chronic
particullarly
challenging,
and
there
lack
knowledge
regarding
their
pathogenesis
treatment.
We
reported
case
who
developed
post-HSCT
nephrotic
syndrome
portal
hypertensive
ascites,
which
are
both
rare
GVHD.
Kidney
biopsy
revealed
membranous
nephropathy
renal
thrombotic
microangiopathy
glomerular
immune
deposits,
suggesting
antibody-mediated
kidney
injury.
Treatment
ruxolitinib
resulted
remission
role
cytokines
the
pathogenesis.
This
highlighted
awareness
ascites
as
GVHD,
efficacy
for
two
manifestations.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(5), P. 2289 - 2289
Published: March 4, 2025
Chronic
graft-versus-host
disease
(cGVHD)
is
a
prognostically
negative
event
following
hematopoietic
stem
cell
transplant
(HSCT).
While
cGVHD
mainly
affects
the
muscles,
skin,
oral
mucosa,
eyes,
lungs,
gastrointestinal
tract,
and
liver,
central
nervous
system
(CNS)
involvement
remains
possible
and,
moreover,
rare
when
it
occurs
isolated.
CNS-cGVHD
can
manifest
with
wide
spectrum
of
CNS
disorders,
including
cerebrovascular
diseases,
autoimmune
demyelinating
immune-mediated
encephalitis.
We
present
case
65-year-old
man
previously
treated
HSCT
presenting
progressive
disorder
optic
neuropathy
without
any
clear
alternative
causal
processes
except
for
microangiopathy
in
context
CNS-cGVHD,
along
suggestive
imaging
instrumental
laboratory
findings.
Starting
one
year
after
acute
myeloid
leukemia,
first
cerebral
ischemic
occurred
was
then
associated
reduction
visual
acuity,
an
extensive
diagnostic
work-up
had
remained
inconclusive
over
many
years,
leading
us
to
hypothesis
therefore,
start
immunosuppressive
therapy.
Our
experience
highlighted
not
ignoring
possibility
as
underlying
mechanism
disorder,
even
absence
other
systemic
presentations,
once
more
common
etiologies
pathological
have
been
ruled
out.
American Journal of Cancer Research,
Journal Year:
2025,
Volume and Issue:
15(1), P. 182 - 194
Published: Jan. 1, 2025
A
novel
reduced-toxicity
conditioning
(RTC)
regimen
of
busulfan,
fludarabine,
cyclophosphamide,
and
antithymocyte
globulin
(Bu/Flu/Cy/ATG)
followed
by
haploidentical
hematopoietic
stem
cell
transplantation
(haplo-HSCT)
in
older
patients
with
hematologic
malignancies
has
been
reported
the
results
was
encouraging.
However,
safety
efficacy
this
unknown
myelodysplastic
neoplasms
(MDS)
patients.
From
January
2018
to
December
2021,
68
consecutive
(aged
over
50)
using
RTC
for
T-cell
replete
haplo-HSCT
(RTC
group)
at
our
center
were
eligible,
aged
under
50
modified
cyclophosphamide
plus
(Bu/Cy/ATG)
(Bu/Cy/ATG
randomly
selected
from
223
MDS
during
same
period
a
1:1
ratio
matched-pair
analysis
patient
sex,
World
Health
Organization
(WHO)
category,
international
prognostic
scoring
system
(IPSS)
risk
group,
time
diagnosis
HSCT,
chemotherapy
advanced,
response
after
chemotherapy,
donor
infused
mononuclear
cells
CD34-positive
count.
The
transplant
outcomes
also
compared
between
group
matched
sibling
(MSD)
(HSCT)
busulfan
(Bu/Cy)
regimen.
cumulative
incidences
grade
II-IV
acute
graft
versus
host
disease
(aGVHD)
significantly
lower
than
that
Bu/Cy/ATG
group.
3-year
treatment
related
mortality
(TRM)
two
groups
12.3%
14.7%
(P=0.613).
relapse,
disease-free
survival
(DFS)
overall
(OS)
comparable
groups.
better
those
received
MSD
transplant,
incidence
TRM,
higher
OS
DFS.
advantages
still
significant
when
comparing
receiving
children
donors
HSCT
TRM.
Children
could
be
choice
Bu/Cy
elderly
encouraging
suggest
is
potentially
promising
method
trail
number
prospective
study
"NCT03412409"
trial
URL
"https://clinicaltrials.gov/study/NCT03412409?term=NCT03412409&rank=1".
JHLT Open,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100209 - 100209
Published: Jan. 1, 2025
Chronic
graft-versus-host
disease
is
a
common
complication
after
allogeneic
hematopoietic
stem
cell
transplantation,
with
pulmonary
chronic
(PcGvHD)
particularly
associated
dismal
prognosis.
Lung
transplantation
(LuTx)
final
therapeutic
option
for
well-selected
patients
affected
by
this
condition.
Nevertheless,
only
small
group
of
PcGvHD
are
referred
LuTx.
This
review
addresses
concerns
regarding
referral
and
listing
LuTx
(such
as
risk
relapse
hematological
malignancy,
infectious
complications
rejection)
survival
outcomes
specific
cohort
patients.
Importantly,
has
comparable
to
other
indications.
The
establishment
indication
criteria
may
improve
rates
timing
both
suitable
candidates.
International Journal of Hematology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 31, 2025
Chronic
graft-versus-host
disease
(cGVHD)
is
a
major
serious
complication
after
allogeneic
stem-cell
transplantation
(allo-HSCT),
and
often
mimics
autoimmune
diseases.
Central
nervous
system
(CNS)
symptoms
are
rare
manifestations
of
cGVHD,
difficult
to
diagnose.
CNS
cGVHD
were
discussed
in
the
2020
National
Institutes
Health
Consensus
Project
as
one
"atypical
manifestations"
with
involvement
various
organ
systems
other
than
classical
organs.
We
experienced
case
myelitis
allo-HSCT
diagnosed
CNS.
The
neurological
progressed
corticosteroid
pulse
therapy,
resulting
severe
paralysis
paresthesia
lower
extremities.
clinical
course
magnetic
resonance
imaging
findings
showed
some
similarities
multiple
sclerosis.
decided
use
rituximab
patient
became
refractory
corticosteroids
because
has
been
reported
be
effective
sclerosis
by
suppressing
B
cells
on
both
sides
blood-brain
barrier.
Rituximab
was
for
neurologic
our
case.
In
atypical
treatments
used
corresponding
diseases
may
reasonable
effective.
Blood Advances,
Journal Year:
2022,
Volume and Issue:
7(14), P. 3612 - 3623
Published: Oct. 11, 2022
The
National
Institutes
of
Health
Consensus
criteria
for
chronic
graft-versus-host
disease
(cGVHD)
diagnosis
can
be
challenging
to
apply
in
children,
making
pediatric
cGVHD
difficult.
We
aimed
identify
diagnostic
biomarkers
that
would
complement
the
current
clinical
and
help
differentiate
from
non-cGVHD.
Applied
Biomarkers
Late
Effects
Childhood
Cancer
(ABLE)
study,
open
at
27
transplant
centers,
prospectively
evaluated
302
patients
after
hematopoietic
cell
(234
evaluable).
Forty-four
developed
cGVHD.
Mixed
fixed
effect
regression
analyses
were
performed
on
onset
blood
samples
cellular
plasma
biomarkers,
with
individual
markers
declared
relevant
if
they
met
3
criteria:
an
ratio
≥1.3
or
≤0.75;
area
under
curve
(AUC)
≥0.60;
a
P
value
<5.814
×
10-4
(Bonferroni
correction)
(mixed
effect)
<.05
(fixed
effect).
To
address
complexity
we
built
machine
learning-based
classifier
combined
multiple
factors.
Decreases
regulatory
natural
killer
cells,
naïve
CD4
T
helper
elevated
levels
CXCL9,
CXCL10,
CXCL11,
ST2,
ICAM-1,
soluble
CD13
(sCD13)
characterize
Evaluation
time
dependence
revealed
sCD13,
ICAM-1
varied
timing
onset.
achieved
AUC
0.89,
positive
predictive
82%
negative
80%
diagnosing
Our
polyomic
approach
building
could
improve
children
but
requires
validation
future
prospective
studies.
This
trial
was
registered
www.clinicaltrials.gov
as
#NCT02067832.
Annals of Hematology,
Journal Year:
2024,
Volume and Issue:
103(4), P. 1403 - 1407
Published: Jan. 29, 2024
Abstract
Isolated
pleural
effusion
is
a
rare
manifestation
of
chronic
graft
versus
host
disease
(cGVHD)
after
hematopoietic
stem
cell
transplantation
(HSCT).
We
herein
report
58-year-old
woman
presenting
with
massive
approximately
1
year
allogeneic
HSCT,
who
was
successfully
treated
corticosteroid.
She
had
discontinued
tacrolimus
month
before
she
presented
effusion,
which
attributed
to
cGVHD
thorough
exclusion
process.
This
case
illustrates
unique
atypical
and
highlights
the
need
for
prompt
therapy
initiation.
Current Oncology,
Journal Year:
2024,
Volume and Issue:
31(3), P. 1426 - 1444
Published: March 8, 2024
This
is
a
consensus-based
Canadian
guideline
whose
primary
purpose
to
standardize
and
facilitate
the
management
of
chronic
graft-versus-host
disease
(cGvHD)
across
country.
Creating
uniform
healthcare
guidance
in
Canada
challenge
for
number
reasons
including
differences
authority
structure,
funding
access
resources
between
provinces
territories,
as
well
geographic
size.
These
can
lead
variable
unequal
effective
therapies
GvHD.
document
will
provide
comprehensive
practical
that
be
applied
by
professionals
caring
patients
with
cGvHD.
Hopefully,
this
guideline,
based
on
input
from
GvHD
treaters
country,
aid
standardizing
cGvHD
care
much-needed
novel
therapies.
consensus
paper
aims
discuss
optimal
approach
initial
assessment
cGvHD,
review
severity
scoring
global
grading
system,
systemic
topical
treatments,
supportive
therapies,
propose
therapeutic
algorithm
frontline
subsequent
lines
treatment
adults
pediatric
patients.
Finally,
we
make
suggestions
about
future
direction
development
such
(1)
mode-of-action-based
drug
selection,
according
pathogenesis
(2)
combination
strategy
introduction
newer
targeted
drugs,
(3)
steroid-free
regimen,
particularly
front
line
therapy
treatment,
(4)
pre-emptive
which
prevent
progression
high-risk
destined
develop
severe
highly
morbid
forms
